Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REZOLVE-AD: Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
2023-507456-69-00Phase 2Authorised
- Sponsor
- Nektar Therapeutics
- Start
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Rezpegaldesleukin with Placebo (2 arms). Primary endpoint: Percent change in EASI from baseline at Week 16. Planned start Apr 2024; status: authorised.
02
Drugs
rezpegaldesleukin
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2023-507456-69-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507456-69-00.